Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perhexiline in HCM with Heart Failure
NCT02862600Phase 2Terminated
- Sponsor
- Heart Metabolics Limited
- Start
- Aug 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of perhexiline in hypertrophic cardiomyopathy (HCM), heart failure (HF), sponsored by Heart Metabolics Limited. Started Aug 2016; status: terminated.
02
Drugs
perhexiline
03
Conditions
hypertrophic cardiomyopathy (HCM)heart failure (HF)
Beyond the preview
Go deeper on NCT02862600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862600.